5332592026-06-115332592026-06-112026-06-115332592026-06-112026-06-11AmalgamatedEntityDomain15332592026-06-11AmalgamatedEntityDomain15332592026-06-112026-06-11AmalgamatedEntityDomain25332592026-06-11AmalgamatedEntityDomain25332592026-06-112026-06-11AmalgamatedEntityDomain35332592026-06-11AmalgamatedEntityDomain35332592026-06-112026-06-11AmalgamatedEntityDomain45332592026-06-11AmalgamatedEntityDomain4xbrli:purexbrli:shares533259HEALTH X PLATFORM LIMITEDHEALTHXNOTLISTEDINE019J01013NewAmalgamation/ Mergertrue2026-06-1016:00:002026-06-11Health X Platform LimitedTransfereeListed Entity (self)As per the standalone audited financials for the year ended 31st March 2026, the Demerged / Transferee Company has total book value of assets of INR 27,102.11 lakhs and a turnover of INR 75.98 lakhs and as per consolidated audited financials for the year ended 31st March 2026, the Demerged/Transferee Company has total book value of assets of INR 93,576.87 lakhs and a turnover of INR 1,37,753.67 lakhs including other income of INR 5,827.08 lakhs.235606270.740782498730.259300318105001235606270.5843167620410.415700403226681Microsec Resources Private LimitedTransfereeSubsidiaryAs per the audited financials for the year ended 31st March 2026, the Resulting/Amalgamated Company has total assets of INR 3,848.31 lakhs and turnover of INR 181.48 lakhs including other income of INR 0.47 lakhs.2581357100002581357178535420.740727499580.259300106035001Innogrow Technologies LimitedTransferorSubsidiaryAs per the audited financials for the year ended 31st March 2026, the Amalgamating Company has total assets of INR 8,953.81 lakhs and turnover consisting of other income of INR 1,331.79 lakhs.33101810000331018100000000Sastasundar Healthbuddy LimitedTransferorMaterial SubsidiaryAs per the audited financials for the year ended 31st March 2026, the Transferor Company has total assets of INR 76,033.74 lakhs and turnover of INR 1,35,969.66 lakhs including other income of 5,620.11 lakhs.171001600.788945758300.21110021675990100000000falsefalsetrue(i) Health X Platform Limited is focusing largely on the following business segments: (a) Financial Services - Engaged in financing of loans, investment in shares and securities, investment in real estate, financial consultancy, professional fees, wealth management, financial planning, distribution and related services. (b) Healthcare Services - Engaged in the business of trading and distribution of medicines and pharmaceutical products to retailers and operating an E-commerce platform for sale of medicines, pharmaceuticals, and diagnostics. (ii) Microsec Resources Private Limited is a registered Non-Deposit Accepting Non-Banking Financial Institution (“NBFI”), a non-banking financial company having Certificate of Registration under RBI Act, 1934. (Certificate of Registration No. being B-05.06241) and is involved in business of financing. (iii) Innogrow Technologies Limited was incorporated to principally engage in the business of providing end-to-end IT, digital technology services and IT-enabled services. (iv) Sastasundar Healthbuddy Limited is principally engaged in the business of trading and distribution of medicine and other pharmaceutical products to various retailers. It also operates an E-commerce platform for sale of medicines, other pharmaceuticals products and diagnostics, through its subsidiary.1. Amalgamation of the Amalgamating Company with and into the Amalgamated Company: The Scheme is intended to restructure these Companies and consolidate their businesses in a manner which is expected to enable better realization of potential of their businesses, yield beneficial results and enhanced value creation for the said Companies, their respective shareholders and stakeholders. This Scheme is in the best interest of the said Companies and their respective shareholders, employees, creditors and other stakeholders on account of following benefits: (a) The business of the Amalgamating Company and the Amalgamated Company can be combined / adjusted and carried forward conveniently with combined strength and would result in consolidation of the Companies, streamlining the corporate structure and pooling of their resources into a single entity. (b) Consolidation of the businesses of the Amalgamating Company and the Amalgamated Company, to achieve optimal and efficient utilization of capital, resulting in lesser overheads including administrative, managerial, and other expenditure, optimal utilization of resources, and provide a common governance structure. (c) Unification and streamlining of legal and regulatory compliances currently required to be carried out by both the Amalgamating Company and the Amalgamated Company. 2. Amalgamation of the Transferor Company with and into the Transferee Company SHBL is engaged in the business of trading and distribution of medicine and other pharmaceutical products to various retailers. SHBL, through its subsidiary, also operates an e-commerce platform for sale of medicines, other pharmaceuticals products and diagnostics. The aforesaid healthcare business of SHBL has been nurtured over a period of time. This Scheme is in the best interest of the Companies and their respective shareholders, employees, creditors and other stakeholders on account of following benefits: (a) As the primary operational entity in the Healthcare Services segment, the amalgamation of the Transferor Company with the Transferee Company will consolidate resources into a single entity and maximize overall shareholder value. (b) Consolidation of the businesses of the Transferor Company and the Transferee Company, for creation of a larger unified entity and to achieve optimal and efficient utilization of capital, resulting in lesser overheads including administrative, managerial, and other expenditure, optimal utilization of resources, and provide a common governance structure. (c) Pooling of knowledge and expertise of both the Companies and align with the business plans to meet long-term objectives and enhance operational and management efficiencies. (d) Unification and streamlining of legal and regulatory compliances currently required to be carried out by both the Transferor Company and the Transferee Company. (e) The amalgamation of the Transferor Company with the Transferee Company will result in the creation of a unified healthcare entity, enabling streamlined management, focused investment decisions, and optimal utilization of cash flows for dividends or capital expenditure in the consolidated healthcare business.Shares8512168:4575830The Share Exchange Ratio and Share Entitlement Ratio has been arrived at based on the valuation report dated 10th June 2026 issued by Mr. Sagar Mehta (Partner, SSPA & Co, Chartered Accountants) (Registration No. IBBI/RV-E/06/2020/126), recommending the Share Exchange Ratio and Share Entitlement Ratio. Jajodia Equity Advisors Services Limited, an independent SEBI registered Category I Merchant Banker (SEBI Regn. No.: INM000013448), has issued a fairness opinion stating that the Share Exchange Ratio and Share Entitlement Ratio is fair from a financial point of view. No shares would be issued for the amalgamation of the Amalgamating Company with and into the Amalgamated Company, as immediately upon the effectiveness of the Demerger, the Amalgamating Company shall become the wholly owned subsidiary of the Amalgamated Company and the entire paid-up share capital of the Amalgamating Company will be held by the Amalgamated Company. Accordingly, upon amalgamation of the Amalgamating Company with and into Amalgamated Company, there will be no issue of shares as consideration for the said amalgamation and the entire share capital of the Amalgamating Company shall stand extinguished and cancelled.Upon the Scheme becoming effective, the Transferee Company will issue equity shares as mentioned in point 6 above to the shareholders of the Transferor Company as on the Record Date (as defined in the Scheme) and all the shares of the Transferor Company shall stand extinguished. Accordingly, upon the Scheme becoming effective, the following change will occur in the shareholding pattern of the Transferee Company (listed entity) i.e. Health X Platform Limited: Pre Scheme:- Promoter & Promoter Group - 2,35,60,627 holding equity shares, constituting 74.07% of the listed entity Public - 82,49,873 holding equity shares, constituting 25.93% of the listed entity Post Scheme:- Promoter & Promoter Group - 2,35,60,627 holding equity shares, constituting 58.43% of the listed entity Public - 1,67,62,041 holding equity shares, constituting 41.57% of the listed entityIn accordance with General Circular No. 30/2014 dated 17th July 2014, issued by the Ministry of Corporate Affairs, transactions resulting from compromises, arrangements, and amalgamations under the Companies Act 2013, are not subject to the requirements of Section 188 of Companies Act, 2013. The transactions contemplated in the Scheme are being undertaken at arms’ length in accordance with the Share Exchange Ratio and Share Entitlement Ratio which has been arrived at based on the valuation report dated 10th June 2026 issued by Mr. Sagar Mehta (Partner, SSPA & Co, Chartered Accountants) (Registration No. IBBI/RV-E/06/2020/126), recommending the Share Exchange Ratio and Share Entitlement Ratio. Jajodia Equity Advisors Services Limited, an independent SEBI registered Category- I Merchant Banker registered with SEBI having Registration Number - INM000013448, has issued a fairness opinion stating that the Share Exchange Ratio and Share Entitlement Ratio is fair from a financial point of view.